Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Breast Cancer

Breast cancer is the most common non-skin cancer among women. The chance of developing invasive breast cancer at some point in a women's life is about 1 in 8 or 13% of women. It is estimated that in 2007 about 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States. Breast cancer is the second leading cause of cancer death in women, exceeded only by lung cancer.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, the efficacy of PROVENGE or sipuleucel-T, the company's lead product candidate to treat men suffering from prostate cancer, the efficacy of NEUVENGE or lapuleucel
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), a leading ... pharmaceutical and biotech industry, has announced that Dr. Mark ... of Director of Science & Technology. , “Mark brings ... drug metabolism and bioanalysis to EZVS in both pharma ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED ... markets advanced in-vitro diagnostic,products, today announced that it will attend ... to October 31, 2009 in Chengdu,China. , , ... 62nd China International Medical Equipment Fair, Date: ...
... a failed terrorist attack in 2006, plane passengers have not ... airports, leaving some parched at the airport and others having ... in Germany is paving the way to eliminate this necessary ... in IOP Publishing,s Superconductor Science and Technology explains ...
... SAN DIEGO, Oct. 20 NuVasive, Inc. ... developing products for minimally disruptive surgical treatments for the spine, ... 2009. , NuVasive reported third quarter revenue of $94.9 million, ... quarter 2008 and a 7.3% increase over the $88.5 million ...
Cached Biology Technology:China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China 20.2 second test for explosive liquids 2NuVasive Reports Third Quarter 2009 Financial Results 2NuVasive Reports Third Quarter 2009 Financial Results 3NuVasive Reports Third Quarter 2009 Financial Results 4NuVasive Reports Third Quarter 2009 Financial Results 5NuVasive Reports Third Quarter 2009 Financial Results 6NuVasive Reports Third Quarter 2009 Financial Results 7NuVasive Reports Third Quarter 2009 Financial Results 8NuVasive Reports Third Quarter 2009 Financial Results 9NuVasive Reports Third Quarter 2009 Financial Results 10NuVasive Reports Third Quarter 2009 Financial Results 11NuVasive Reports Third Quarter 2009 Financial Results 12
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 The Defense ... easier to detect and prevent counterfeit microcircuits from entering ... started performing an in-house microcircuit anti-counterfeit initiative dubbed DNA ... microcircuits while increasing their reliability throughout the supply chain. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... world,s first three-dimensional plasmon rulers, capable of measuring ... developed by researchers with the U.S. Department of ... in collaboration with researchers at the University of ... scientists with unprecedented details on such critical dynamic ...
... knows, the pharmaceutical industry is struggling to deal with ... well known is the similar struggle in agribusiness to ... herbicide that is widely used in farming practice. ... active ingredient in Monsanto,s Roundup products and also in ...
... LANSING, Mich. Sheng Yang He, plant biologist at ... nation,s most-innovative plant scientists as part of a $75 ... Hughes Medical Institute and the Gordon and Betty Moore ... Research Laboratory, and 14 other researchers from around the ...
Cached Biology News:Taking the 3-D measure of macromolecules: 2Taking the 3-D measure of macromolecules: 3Scientists learn how horseweed shrugs off herbicide 2Scientists learn how horseweed shrugs off herbicide 3Scientists learn how horseweed shrugs off herbicide 4Scientists learn how horseweed shrugs off herbicide 5MSU plant scientist named one of the nation's most innovative researchers 2
... quality microarray scanner based on patented confocal laser ... resolution. The DNAscope LM is unique because ... that is upgradeable to a total of 3 ... Includes control module (computer), monitor, and software ...
... PATH™ Protein Microarray Slide features an ... The,PATH™ Slide is the first protein ... benefits of nitrocellulose in a thin ... signal-to-noise ratios. ,The PATH™ Slide ...
Request Info...
... for Alkaline Phosphatase conjugates. The product ... both the enzyme and the antibody following ... product has been chemically engineered to increase ... shelf life, resistance to various shipping conditions ...
Biology Products: